Current Report Filing (8-k)
2018年11月10日 - 7:01AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 9, 2018 (November 7, 2018)
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
November 7, 2018, effective as of November 8, 2018, Akers Biosciences, Inc. (the “
Company
”) filed a Certificate
of Amendment (the “
Certificate of Amendment
”) to its Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of New Jersey to effect a reverse stock split of its common stock at a ratio of eight-for-one
(8-for-1).
As a result of the reverse stock split, there are approximately
12,474,028
shares of common stock outstanding. The reverse stock split affected all stockholders uniformly
and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse
stock split would have resulted in a stockholder owning a fractional share. Fractional shares have not been issued as a result
of the reverse stock split; instead, the board of directors of the Company determined to effect an issuance of shares to holders
that would otherwise have been entitled to a fractional share such that any fractional shares were rounded up to the nearest whole
number.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
November 9, 2018
|
By:
|
/s/
Howard R. Yeaton
|
|
|
Howard
R. Yeaton
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 8 2024 まで 9 2024
Akers Biosciences (NASDAQ:AKER)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Akers Biosciences Inc (ナスダック市場): 0 recent articles
その他のAkers Biosciences, Inc.ニュース記事